Showing 1260 – 1270 of 1303 results
-
Vaccitech plc Initiation
William Blair initiated research coverage of Vaccitech plc (VACC $14.58). Vaccitech is a clinical-stage biotechnology company that develops immunotherapeutics by leveraging its proprietary chimpanzee adenovirus and Modified Vaccinia Ankara T-cell-inducing platform. Areas of focus include therapeutic and prophylactic programs in the infectious disease and oncology space.
-
Behavioral Healthcare Robust Demand and Ripe for Innovation
Following the COVID-19 pandemic, the behavioral healthcare industry has experienced an unprecedented surge in the need for innovation, increased access to care, and demand for services.
-
Rubrik Inc Initiation
William Blair initiated research coverage of Rubrik, Inc. (RBRK $75.59), a leading vendor in the fast-evolving data protection (DP) industry, pioneering a next-generation approach to data backup and transforming perceptions of DP technology from “boring old backup” to a must-have cyber resilience platform.
-
Q&A on Coronavirus Testing with William Blair’s Equity Analyst Brian Weinstein
Lead equity analyst covering COVID-19 diagnostics shares latest developments.
-
Waystar Holding Corp Initiation
William Blair initiated research coverage of Waystar Holding Corp. (WAY $21.50), a leading provider of end-to-end revenue cycle management (RCM) software solutions, partnering with hospital systems and ambulatory care providers to drive superior RCM performance from patient financial clearance and price transparency all the way through final cash collections.
-
Skyward Specialty Insurance Group Inc Initiation
William Blair initiated research coverage of Skyward Specialty Insurance Group, Inc. (SKWD $37.21), a specialty insurance company that writes complex risks in underserved commercial markets.
-
Tenax Therapeutics Inc Initiation
William Blair initiated research coverage of Tenax Therapeutics, Inc. (TENX $3.45). Tenax is focused on pulmonary and cardiovascular diseases, including lead program levosimendan for the treatment of pulmonary hypertension in patients with heart failure with preserved ejection fraction (PH-HFpEF).
-
Upstream Bio Inc Initiation
William Blair initiated research coverage of Upstream Bio, Inc. (UPB $24.76), which is developing the differentiated TSLP receptor antibody verekitug for multiple inflammatory pulmonary diseases, including asthma and COPD.
-
CeriBell Inc Initiation
William Blair initiated research coverage of CeriBell, Inc. (CBLL $26.42). The Ceribell ecosystem is an AI-powered point-of-care electroencephalography (EEG) device used in the detection of seizures and other neurological conditions in the acute-care setting.
-
CAMP4 Therapeutics Inc Initiation
William Blair initiated research coverage of CAMP4 Therapeutics, Inc. (CAMP $10.05). Camp4 is pioneering therapies for rare diseases by harnessing recently discovered regulatory RNA (regRNA) to modulate epigenetic expression of genetic targets.